## October 29, 2013

## Presentation for Investors

## 1H FY2013 (April 1 - September 30, 2013) Financial Results

Translation of presentation materials for the investor meeting held in Tokyo on October 29, 2013
(\#billion)

| 1H FY2013 <br> Outlook as of <br> May 2013 | 1H FY2013 <br> Outlook as of <br> July 2013 |
| ---: | ---: |
| 72.0 | 75.0 |
| 8.7 | 9.5 |
| 0.1 | 0.3 |
| 8.8 | 9.8 |
| - | - |
| 6.3 | 7.0 |
| 12.9 | - |
| 38.48 | 42.75 |
| $¥ 12$ | $¥ 12$ |
| 2.0 | 2.0 |
| $12.1 \%$ | $12.7 \%$ |
| 85 | - |
| 61,000 | - |


| Comprehensive Income | 5.0 | 10.0 |
| :--- | ---: | ---: |

(1) EBITDA $=$ Operating Profit + Depreciation
(2) Based on Trade Statistics of Japan Ministry of Finance (1H FY2013: Based on April-August actual)

## 1H FY2013 Review

## <vs. 1H FY2012>

(Sales) Up $¥ 5.3$ billion (+7.4\%) (+) Chemicals, Performance Materials, Agrochemicals, Pharmaceuticals, Trading
$(\mathrm{OP}) \triangleleft$ Up $¥ 2.0$ billion $(+23.3 \%)(+)$ Performance Materials, Agrochemicals, Pharmaceuticals $( \pm)$ Chemicals, Trading
(Non-Operating
Income and Expenses) Up $¥ 0.7$ billion
(Ordinary Income) Up $¥ 2.7$ billion (+32.6\%)
(Net Income) Up $¥ 2.4$ billion (+41.5\%)
$\diamond$ OP, Ordinary Income, Net Income renewed the highest results for 1H recorded in 1H FY2008
<vs. 1H FY2013 Outlook as of May 2013>
(Sales) Up $¥ 4.4$ billion
(+) Chemicals, Performance Materials, Agrochemicals, Pharmaceuticals, Trading
(OP) $\downarrow$ Up $¥ 1.9$ billion
(Non-Operating
Income and Expenses) Up $¥ 0.4$ billion
(Ordinary Income) Up $¥ 2.3$ billion
(Net Income) Up $¥ 1.7$ billion
<vs. 1H FY2013 Outlook as of July 2013 >
(Sales) Up $¥ 1.4$ billion
(OP)
$\bullet$ Up $¥ 1.1$ billion
(Net Income) Up $¥ 1.0$ billion
<Dividend> $>\neq 14 /$ share (up $¥ 2$ vs. 1H FY2012 Actual and 1H FY2013 Outlook as of May 2013)
(-) Chemicals
(+) Performance Materials, Agrochemicals, Pharmaceuticals, Trading
$(-)$ Chemicals
(Ordinary Income) $\downarrow$ Up $¥ 1.3$ billion

## 1H FY2013

## Non-Operating Income/Expenses, Extraordinary Profit/Loss, Comprehensive Income <br> (¥billion)

|  | $1 H$ <br> FY2012 | $1 H$ <br> FY2013 | Change |
| :--- | ---: | ---: | ---: |
| Non-Operating Income | 1.13 | 1.38 | 0.25 |
| Interest income, dividend income | 0.31 | 0.28 | -0.03 |
| Equity in earnings of affiliates | 0.30 | 0.38 | 0.08 |
| Gain on foreign exchange | 0.00 | 0.23 | 0.23 |
| Others | 0.52 | 0.49 | -0.03 |
| Non-Operating Expenses | 1.32 | 0.84 | -0.48 |
| Interest expense | 0.19 | 0.16 | -0.03 |
| Loss on disposal of fixed assets | 0.16 | 0.15 | -0.01 |
| Losson revaluation of investments in securities | 0.26 | 0.00 | -0.26 |
| Loss on foreign exchange | 0.27 | 0.00 | -0.27 |
| Others | 0.44 | 0.53 | 0.09 |


| Extraordinary Profit | - | - | - |
| :--- | ---: | ---: | ---: |
| Extraordinary Loss | - | - | - |


| Com prehensive Income | 5.00 | 10.00 | 5.00 |
| :--- | ---: | ---: | ---: |
| Net income | 5.63 | 7.96 | 2.33 |
| Minority interests | 0.04 | 0.09 | 0.05 |
| Unrealized gains or losses on investment securities | -0.57 | 1.40 | 1.97 |
| Foreign currency translation adjustments | -0.10 | 0.55 | 0.65 |

## 1H FY2013 Cash Flow

(¥billion)

|  | (\#billion) |  |
| :---: | :---: | :---: |
|  | $\begin{gathered} \hline \text { 1H } \\ \text { FY2012 } \end{gathered}$ | $\begin{gathered} \text { 1H } \\ \text { FY2013 } \end{gathered}$ |
| CF from operating activities | 21.9 | 22.7 |
| Profit before income tax | 8.4 | 11.1 |
| Depreciation \& amortization | 4.4 | 4.0 |
| Tax | -1.9 | -3.9 |
| Working capital, others | 11.0 | 11.5 |
| CF from investing activities | -4.8 | -7.7 |
| Purchase of PPE | -3.9 | -4.1 |
| Others | -0.9 | -3.6 |
| CF from financing activities | -22.6 | -19.1 |
| Dividends paid | -2.0 | -2.3 |
| Borrowings | -15.5 | -16.7 |
| Purchase of treasury shares | -5.0 | 0.0 |
| Others | -0.1 | -0.1 |
| Effect of FX rate changes on cash \& cash equivalents | -0.1 | 0.2 |
| Change in cash \& cash equivalents | -5.6 | -3.9 |
| Cash \& cash equivalents at end of period | 22.3 | 28.0 |

## 1H FY2013 Balance Sheets

(¥billion)

|  | 2012/9 | $\begin{gathered} 2013 / 3 \\ A \end{gathered}$ | $\begin{gathered} \text { 2013/9 } \\ B \end{gathered}$ | Change <br> B - A |
| :---: | :---: | :---: | :---: | :---: |
| Current assets | 101.0 | 125.9 | 108.1 | -17.8 |
| Cash | 22.3 | 31.9 | 28.0 | -3.9 |
| Accounts receivable | 43.4 | 56.7 | 42.1 | -14.6 |
| Inventories | 30.1 | 30.6 | 31.5 | 0.9 |
| Others | 5.2 | 6.7 | 6.5 | -0.2 |
| Fixed assets | 72.5 | 73.3 | 79.3 | 6.0 |
| Total PPE | 45.8 | 44.0 | 44.8 | 0.8 |
| Intangible assets | 2.4 | 2.0 | 1.6 | -0.4 |
| Investment securities | 21.5 | 24.9 | 31.1 | 6.2 |
| Others | 2.8 | 2.4 | 1.8 | -0.6 |
| Total assets | 173.5 | 199.2 | 187.4 | -11.8 |


|  | 2012/9 | $\begin{gathered} 2013 / 3 \\ A \end{gathered}$ | $\begin{gathered} 2013 / 9 \\ B \end{gathered}$ | Change B - A |
| :---: | :---: | :---: | :---: | :---: |
| Liabilities | 56.0 | 72.5 | 53.1 | -19.4 |
| Accounts payable | 14.8 | 17.4 | 14.4 | -3.0 |
| Borrowings | 23.4 | 38.1 | 21.4 | -16.7 |
| Others | 17.8 | 17.0 | 17.3 | 0.3 |
| Net assets | 117.5 | 126.7 | 134.3 | 7.6 |
| Shareholders' equity | 116.6 | 122.9 | 128.6 | 5.7 |
| Unrealized gains or losses on inv estment securities | 1.5 | 3.5 | 4.9 | 1.4 |
| Foreign currency translation adjustments | -1.5 | -0.8 | -0.3 | 0.5 |
| Minority interests | 0.9 | 1.1 | 1.1 | 0.0 |
| Total liabilities \& Net assets | 173.5 | 199.2 | 187.4 | -11.8 |
| - Equity Ratio <br> - D/E Ratio (1) | $\begin{array}{r} \hline 67.2 \% \\ 1.0 \% \end{array}$ | 63.0\% 5.0\% | $\begin{gathered} \hline 71.1 \% \\ -5.1 \% \end{gathered}$ |  |

. Change in shareholders' equity 5.7
= Net Income 8.0 - Dividend 2.3
(1)D/E Ratio $=($ Borrowings - Cash) $/$ Shareholders' equity
(Blank)

## FY2013 Outlook

|  | FY2012 |  |  | FY2013 Outlook as of Oct 2013 |  |  | Change |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1H | 2H | Total | 1H | 2HE | Total | 1H | 2HE | Total |
| Sales | 71.1 | 82.7 | 153.8 | 76.4 | 86.1 | 162.5 | 5.3 | 3.4 | 8.7 |
| Operating Profit | 8.6 | 10.9 | 19.5 | 10.6 | 11.4 | 22.0 | 2.0 | 0.5 | 2.5 |
| Non-Operating Income/Expenses | -0.2 | 1.2 | 1.0 | 0.5 | 0.5 | 1.0 | 0.7 | -0.7 | 0.0 |
| Ordinary Income | 8.4 | 12.1 | 20.5 | 11.1 | 11.9 | 23.0 | 2.7 | -0.2 | 2.5 |
| Extraordinary Profit/Loss (1) | - | - | - | - | -0.3 | -0.3 | - | -0.3 | -0.3 |
| Net Income | 5.6 | 8.3 | 13.9 | 8.0 | 8.0 | 16.0 | 2.4 | -0.3 | 2.1 |
| EBITDA (2) | 13.0 | 16.0 | 29.0 | 14.6 | 16.0 | 30.6 | 1.6 | 0.0 | 1.6 |
| EPS ( $~$ ) | 33.63 | 50.11 | 83.74 | 48.62 | 49.10 | 97.72 | 14.99 | -1.01 | 13.98 |
| Dividend ( $¥ /$ share) | ¥12 | ¥14 | ¥26 | ¥14 | ¥14 | ¥28 | ¥2 | ¥0 | ¥2 |
| Total amount of Dividend | 2.0 | 2.3 | 4.3 | 2.3 | 2.3 | 4.6 | 0.3 | 0.0 | 0.3 |
| OP Margin (\%) | 12.1\% | 13.3\% | 12.7\% | 13.8\% | 13.2\% | 13.5\% | 1.7\% | -0.1\% | 0.8\% |
| ROE(\%) | - | - | 11.4\% | - | - | 12.2\% |  |  |  |
| FX Rate ( $~ / ~ / \$$ ) | 79 | 87 |  | 99 | 100 |  |  |  |  |
| Naphtha ( $¥ / \mathrm{kl}$ ) | 54,800 | 59,800 |  | 64,600 | 63,600 |  |  |  |  |

(¥billion)

| FY2013 Outlook as of May 2013 |  |  | FY2013 <br> Outlook as of July 2013 |
| :---: | :---: | :---: | :---: |
| 1HE | 2HE | Total | 1HE |
| 72.0 | 84.0 | 156.0 | 75.0 |
| 8.7 | 11.7 | 20.4 | 9.5 |
| 0.1 | 0.5 | 0.6 | 0.3 |
| 8.8 | 12.2 | 21.0 | 9.8 |
| - | - | - |  |
| 6.3 | 8.6 | 14.9 | 7.0 |
| 12.9 | 16.3 | 29.2 |  |
| 38.48 | 52.52 | 91.00 | 42.75 |
| $¥ 12$ | $¥ 14$ | ¥26 | ¥12 |
| 2.0 | 2.3 | 4.3 | 2.0 |
| 12.1\% | 13.9\% | 13.1\% | 12.7\% |
| - | - | 11.4\% | - |
| 85 | 85 |  | - |
| 61,000 | 61,000 |  | - |


| Comprehensive Income | 5.0 | 11.1 | 16.1 | 10.0 |
| :--- | ---: | ---: | ---: | ---: |

[^0]
## 2H FY2013 Outlook

```
<vs. 2H FY2012>
    (Sales) Up ¥3.4 billion(+4.1%) (+) Chemicals, Performance Materials, Agrochemicals, Trading
    (-) Pharmaceuticals
    (OP)
    (Non-Operating
    Income and Expenses)
        (Ordinary Income)
        (Extraordinary
        Profit and Loss)
            (Net Income) Down ¥0.3 billion(-3.1%)
```

<vs. 2H FY2013 Outlook as of May 2013>
(Sales)
(OP)
(Ordinary Income)
-Down $¥ 0.3$ billion
(Extraordinary Profit and Loss)
(Net Income)
-Down $¥ 0.6$ billion
(+) Performance Materials, Agrochemicals, Trading (-) Chemicals, Pharmaceuticals
( $\pm$ ) Agrochemicals, Pharmaceuticals (-) Chemicals, Performance Materials, Trading

Asset impairment loss- 0.3 by Nissan Chemical America

## <Dividend>

- $¥ 14 /$ share (Same as 2H FY2012 Actual and 2H FY2013 Outlook as of May 2013)


## Full Year FY2013 Outlook

## <vs. FY2012>

(Sales) Up $¥ 8.7$ billion(+5.7\%) (+) Chemicals, Performance Materials, Agrochemicals, Trading $(-)$ Pharmaceuticals
(OP) >Up $¥ 2.5$ billion(+12.5\%)
(+) Chemicals, Performance Materials, Agrochemicals
$( \pm)$ Trading
$(-)$ Pharmaceuticals
(Ordinary Income) 《Up $¥ 2.5$ billion(+12.2\%)
(Extraordinary Down $¥ 0.3$ billion Profit and Loss)
(Net Income) >Up $¥ 2.1$ billion(+15.3\%)
<vs. FY2013 Outlook as of May 2013>
(Sales) Uu $¥ 6.5$ billion (+) Chemicals, Performance Materials, Agrochemicals, Trading $( \pm)$ Pharmaceuticals
(OP) ©Up $¥ 1.6$ billion
(+) Performance Materials, Agrochemicals, Pharmaceuticals
$( \pm)$ Trading
$(-)$ Chemicals
(Non-Operating $\quad$ Up $¥ 0.4$ billion
Income and Expenses)
(Ordinary Income) *Up $¥ 2.0$ billion
(Extraordinary Down $¥ 0.3$ billion Asset impairment loss $\mathbf{- 0 . 3}$ by Nissan Chemical America
Profit and Loss)
(Net Income) 《Up $¥ 1.1$ billion
$<$ Dividend $>\quad\langle ¥ 28 /$ share (up $¥ 2$ vs. FY2012 Actual and FY2013 Outlook as of May 2013)

## FY2013 Cash Flow Outlook

|  | FY2012 | FY2013 <br> Outlook as of <br> Oct 2013 | FY2013 <br> Outlook as of <br> May2013 |
| :--- | ---: | ---: | ---: |
| CF from operating activities | 22.8 | 20.6 | 20.0 |
| Profit before income tax | 20.5 | 23.0 | 21.0 |
| Depreciation \& Amortization | 9.5 | 8.6 | 8.8 |
| Tax | -4.4 | -7.3 | -6.7 |
| Working capital, others | -2.8 | -3.7 | -3.1 |
| CF from inve sting activities | -9.3 | -14.0 | -11.6 |
| Purchase of PPE | -8.0 | -10.4 | -9.5 |
| Others | -1.3 | -3.6 | -2.1 |
| CF from financing activities | -9.8 | -6.7 | -6.3 |
| Dividends paid | -4.0 | -4.6 | -4.3 |
| Borrowings | -0.8 | -2.0 | -2.0 |
| Purchase of treasury shares | -5.0 | 0.0 | 0.0 |
| Others | 0.0 | -0.1 | 0.0 |
| Effect of FX rate changes on cash \& cash equivalents | 0.3 | 0.2 | 0.0 |
| Change in cash \& cash equivalents | 4.0 | 0.1 | 2.1 |
| Cash \& cash equivalents at end of period | 31.9 | 32.0 | 34.0 |

## New Segmentation (From 2Q 2011)

-Reflecting organizational changes implemented in June 2011
-Major organizational change
Creation of Performance Materials Division to consolidate Electronic Materials Division and Inorganic Materials Division aiming to strengthen performance materials business which is identified as our major growth engine

- Major changes in segmentation

Creation of Performance Materials
Change in Chemicals
$\rightarrow$ Electronic Materials + Inorganic Materials
$\rightarrow$ Inorganic Materials shifted to Performance Materials Creation of Fine Chemicals subsegment, abolishment of Organic Materials subsegment Environmental Chemicals (HI-LITE) shifted from basic Chemicals to Fine Chemicals

| Former Segmentation |  |  |
| :---: | :---: | :---: |
| Segment | Main Products |  |
| Chem | Organic Materials | TEPIC <br> Melamine cyanurate Custom Chemicals |
|  | Inorganic Materials | SNOWTEX <br> Organo sillica sol Alumina sol SUNCOLLOID CELNAX |
|  | Basic Chemicals | Melamine Urea, AdBlue HI-LITE <br> Ammonia, Sulfuric acid, Nitric acid High purity chemicals |
| Electronic Materials | SUNEVER, BARCNHCMulti layer process materialsMicro lens |  |
| Agro Chem | Agro | Herbicides Insecticides Fungicide |
| Pharma | LIVALO |  |
| Trading | Nissei Corporation |  |
| Others | Nissan Butsuryu, Nissan Green \& Landscape, Nissan Engineering, Fertilizer |  |
| Adjustment | R\&D expenses of Advanced Materials \& Planning Dept. included |  |


| New Segmentation |  |  |
| :---: | :---: | :---: |
| Segment | Main Products |  |
| Chem | Fine Chemicals | TEPIC <br> Melamine cyanurate HI-LITE Custom Chemicals |
|  | Basic Chemicals | Melamine Urea, AdBlue Ammonia, Sulfuric acid, Nitric acid High purity chemicals |
| Performance Materials | SUNEVER, BARC, NHC, Multi layer process materials Micro lens <br> SNOWTEX, Organo sillica sol Alumina sol, SUNCOLLOID CELNAX |  |
| Agro Chem | Agro | Herbicides Insecticides Fungicide |
| Pharma | LIVALO |  |
| Trading | Nissei Corporation |  |
| Others | Nissan Butsuryu, Nissan Green \& Landscape, Nissan Engineering, Fertilizer |  |
| Adjustment | R\&D expenses of Advanced Materials \& Planning Dept. included |  |

## Diversified Product Portfolio

Consisting of products holding strong position in market
( $¥$ billion)

| FY2012 Sales |  |  | TEPIC | Epoxy compound for painting, LED sealant, solder resist |
| :---: | :---: | :---: | :---: | :---: |
| C | Fine | 11.2 |  | Agents for cleaning semiconductors |
| h | Chemicals | (7.3\%) | sulfuric acid |  |
| e | Basic | 25.4 | AdBlue | Urea to reduce NOx for diesel trucks |
| m | Chemicals | (16.5\%) |  |  |
| Performance Materials |  | $\begin{array}{r} 37.4 \\ (24.3 \%) \end{array}$ | SUNEVER | LCD alignment coating |
|  |  | BARC | Bottom-anti-reflective coating for semiconductor |  |
| Agro |  |  | $\begin{array}{r} 35.4 \\ (23.0 \%) \end{array}$ | SNOWTEX | Silica sol for polishing silicon wafer, catalyst, non-chrome electrical steel |
| Pharma |  | $\begin{array}{r} 10.6 \\ (6.9 \%) \end{array}$ |  |  |
|  |  | ROUNDUP | Non-selective herbicide |  |
| Trading |  |  | 46.6 $(30.3 \%)$ | SIRIUS | Paddy rice herbicide |
| Others |  | $\begin{array}{r} 21.2 \\ (13.8 \%) \end{array}$ | LIVALO | Anti-cholesterol drug |
|  |  |  |  |  |

NCI's Position

Largest (World)

Largest (Japan)
Among top 3 (Japan)

Major (Asia)
Largest (Asia)
Largest (Japan)

Largest (Japan)
No. 3 (Japan)

No. 3 (Japan)

## FY2013 Sales Outlook by Segment

(¥billion)

|  | FY2012 |  |  | FY2013 Outlook as of Oct 2013 |  |  | Change |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1H | 2H | Total | 1H | 2HE | Total | 1H | 2HE | Total |
| Chem | 17.9 | 18.7 | 36.6 | 18.6 | 19.2 | 37.8 | 0.7 | 0.5 | 1.2 |
| Fine Chemicals | 5.6 | 5.6 | 11.2 | 6.0 | 5.8 | 11.8 | 0.4 | 0.2 | 0.6 |
| Basic Chemicals | 12.3 | 13.1 | 25.4 | 12.6 | 13.4 | 26.0 | 0.3 | 0.3 | 0.6 |
| Performance Materials | 18.8 | 18.6 | 37.4 | 20.6 | 21.9 | 42.5 | 1.8 | 3.3 | 5.1 |
| Agro | 13.4 | 22.0 | 35.4 | 16.0 | 22.9 | 38.9 | 2.6 | 0.9 | 3.5 |
| Pharma | 5.3 | 5.3 | 10.6 | 5.7 | 4.4 | 10.1 | 0.4 | -0.9 | -0.5 |
| Trading | 22.7 | 23.9 | 46.6 | 24.5 | 25.2 | 49.7 | 1.8 | 1.3 | 3.1 |
| Others | 10.2 | 11.0 | 21.2 | 9.7 | 11.3 | 21.0 | -0.5 | 0.3 | -0.2 |
| Adj ustment | -17.2 | -16.8 | -34.0 | -18.7 | -18.8 | -37.5 | -1.5 | -2.0 | -3.5 |
| Total | 71.1 | 82.7 | 153.8 | 76.4 | 86.1 | 162.5 | 5.3 | 3.4 | 8.7 |


| FY2013 Outlook <br> as of May 2013 |  |  | FY2013 Outlook <br> as of July 2013 |
| ---: | ---: | ---: | ---: |
| 1 H E | 2H E | Total | 1H E |
| 17.9 | 19.7 | 37.6 | 18.8 |
| 5.8 | 6.2 | 12.0 | - |
| 12.1 | 13.5 | 25.6 | - |
| 19.6 | 20.3 | 39.9 | 20.4 |
| 13.4 | 22.8 | 36.2 | 14.5 |
| 5.6 | 4.5 | 10.1 | 5.7 |
| 23.7 | 25.0 | 48.7 | 23.7 |
| 9.8 | 11.5 | 21.3 | 9.8 |
| -18.0 | -19.8 | -37.8 | -17.9 |
| 72.0 | 84.0 | 156.0 | 75.0 |

## FY2013 OP Outlook by Segment

(¥billion)

|  | FY2012 |  |  | FY2013 Outlook as of Oct 2013 |  |  | Change |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1H | 2H | Total | 1H | 2HE | Total | 1H | 2HE | Total |
| Chem | 0.8 | 1.1 | 1.9 | 0.8 | 1.6 | 2.4 | 0.0 | 0.5 | 0.5 |
| Performance Materials | 4.1 | 3.1 | 7.2 | 4.4 | 3.6 | 8.0 | 0.3 | 0.5 | 0.8 |
| Agro | 1.3 | 3.7 | 5.0 | 2.4 | 3.8 | 6.2 | 1.1 | 0.1 | 1.2 |
| Pharma | 2.6 | 2.6 | 5.2 | 3.1 | 2.0 | 5.1 | 0.5 | -0.6 | -0.1 |
| Trading | 0.7 | 0.7 | 1.4 | 0.7 | 0.7 | 1.4 | 0.0 | 0.0 | 0.0 |
| Others | 0.1 | 0.6 | 0.7 | 0.2 | 0.5 | 0.7 | 0.1 | -0.1 | 0.0 |
| Adjustment | -1.0 | -0.9 | -1.9 | -1.0 | -0.8 | -1.8 | 0.0 | 0.1 | 0.1 |
| Total | 8.6 | 10.9 | 19.5 | 10.6 | 11.4 | 22.0 | 2.0 | 0.5 | 2.5 |


| FY2013 Outlook <br> as of May 2013 |  |  | FY2013 Outlook <br> as of July2013 |
| ---: | ---: | ---: | ---: |
| 1H E | 2 H E | Total | 1H E |
| 0.9 | 1.7 | 2.6 | 1.0 |
| 3.5 | 3.7 | 7.2 | 3.8 |
| 1.4 | 3.8 | 5.2 | 1.7 |
| 2.9 | 2.0 | 4.9 | 3.0 |
| 0.6 | 0.8 | 1.4 | 0.6 |
| 0.0 | 0.4 | 0.4 | 0.0 |
| -0.6 | -0.7 | -1.3 | -0.6 |
| 8.7 | 11.7 | 20.4 | 9.5 |

## Chemicals - (A) Flow Chart of Selected Basic and Fine Chemicals Products

$\checkmark$ Core products of Basic Chemicals : Ammonia related products and sulfuric acid related products

- FY2012 ammonia domestic market share 9\%, high percentage of self-consumption of ammonia

$==\begin{aligned} & \text { Basic } \\ & \text { Chemicals }\end{aligned}$

(agent used for sterilizing, disinfectant for
 swimming pool and water purification tanks)


## Chemicals - (B) 1H FY2013 Sales Distribution



## Main Products

Fine ChemicalsBasic Chemicals

- Melamine

Environmental related products
TEPIC

- Ammonia
- High purity sulfuric acid
- Sulfuric acid

Custom
Chemicals
Orea including AdBlue

- Nitric acid
- FINEOXOCOL


## Chemicals - (C) Fine Chemicals Subsegment

## 1H FY2013 Sales Review

<vs. 1H FY2012> TEPIC
: Due to weak yen, sales for general applications and electronic materials up

- Environmental related products : Strong domestic demand, and increase in export due to weak yen
- Custom Chemicals : Down due to customers inventory adjustments


## 2H FY2013 Sales Outlook

## <vs. 2H FY2012> TEPIC

: Sales for both general applications and electronic materials up
$\checkmark$ Environmental related products :
Export expected to increase due to weak yen, domestic sales marginally up

- Custom Chemicals
: Down due to customers inventory adjustments

|  |  |  | Sal | es YO | Chan |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Main Products |  |  | $\begin{aligned} & \text { look } \\ & 013 \end{aligned}$ | $\begin{aligned} & \text { FY20 } \\ & \text { as ot } \end{aligned}$ | 13 Out <br> May 2 | $\begin{aligned} & \text { look } \\ & 013 \end{aligned}$ |
|  |  | 1H | 2H E | Total | 1H E | 2H E | Total |
| Total Subsegment |  | +7\% | +4\% | +5\% | +3\% | +11\% | +7\% |
| TEPIC | Epoxy compound for : <br> (A) electronic materials (solder resist, LED sealant), <br> (B) general applications such as powder coating agent for paint (automobiles, electric appliances) <br> World largest producer | +18\% | +22\% | +20\% | +8\% | +18\% | +13\% |
| Env ironmental related products | $\bullet$ HI-LITE : made from chlorinated isocyanuric acid, used for sterilizing, disinfectant for swimming pool as well as water purification tank | +16\% | +7\% | +12\% | +11\% | +2\% | +7\% |
| Custom Chemicals | Custom manufacturing and process researching services for pharmaceutical ingredients and intermediaries from pre-clinical to commercial production stages | -29\% | -22\% | -25\% | -25\% | +12\% | -5\% |

Three products account for 78\% of total consolidated subsegment sales (FY2012)

## Chemicals - (D) Basic Chemicals Subsegment

## 1H FY2013 Sales Review

<vs. 1H FY2012> Melamine

- Urea including AdBlue
: Domestic sales up due to recovery in housing construction, export up due to weak yen
- Urea including AdBlue : Increase continuing

High purity sulfuric acid: Down due to lower domestic semiconductors production

## 2H FY2013 Sales Outlook

<vs. 2H FY2012> Melamine : Domestic sales flat, export expected to decline due to weaker Asian market

- Urea including AdBlue : Increase continuing
- High purity sulfuric acid : Up due to production increase of certain domestic customers

|  |  |  | Sal | es YO | Cha |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Main Products | $\begin{aligned} & \text { FY2 } \\ & \text { as } \end{aligned}$ | $\begin{aligned} & 013 \text { Outl } \\ & \text { of Oct } 20 \end{aligned}$ |  |  |  |  |
|  |  | 1H | 2 HE | Total | 1H E | 2H E | Total |
| Total Subsegment |  | +2\% | +3\% | +2\% | -1\% | +3\% | +1\% |
| Melamine | Mainly used as adhesive agent for particle board, medium density fiberboard, plyw ood | +41\% | -1\% | +15\% | +24\% | -10\% | +4\% |
| Urea including AdBlue | Urea: mainly used for urea formaldehyde resin, adhesive agent <br> - AdBlue: solution of urea in demineralised water for diesel trucks to reduce Nox | +10\% | +11\% | +11\% | +15\% | +17\% | +16\% |
| High purity sulfuric acid | Used to clean semiconductors <br> Largest in domestic market | -7\% | +11\% | +1\% | -2\% | +13\% | +5\% |

Three products account for 34\% of total consolidated subsegment sales(FY2012)

## Chemicals - (E) Profit Overview

|  | FY2012 |  |  | FY2013 Eas of Oct 2013 |  |  | Change |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1H | 2H | Total | 1H | 2HE | Total | 1H | 2HE | Total |
| Sales | 17.9 | 18.7 | 36.6 | 18.6 | 19.2 | 37.8 | 0.7 | 0.5 | 1.2 |
| Fine Chemicals | 5.6 | 5.6 | 11.2 | 6.0 | 5.8 | 11.8 | 0.4 | 0.2 | 0.6 |
| Basic Chemicals | 12.3 | 13.1 | 25.4 | 12.6 | 13.4 | 26.0 | 0.3 | 0.3 | 0.6 |


| OP | 0.8 | 1.1 | 1.9 | 0.8 | 1.6 | 2.4 | 0.0 | 0.5 | 0.5 |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |


| FY2013 E <br> as of May2013 |  |  | FY2013 E <br> as of July2013 |
| ---: | ---: | ---: | :---: |
| 1H E | 2H E | Total | 1H E |
| 17.9 | 19.7 | 37.6 | 18.8 |
| 5.8 | 6.2 | 12.0 | - |
| 12.1 | 13.5 | 25.6 | - |

## 1H FY2013 Review <br> <vs. 1H FY2012>

## (Fine Chemicals)

- Sales of TEPIC and environmental related products up, sales of Custom Chemicals down, fixed cost down
$\checkmark$ Sales up, OP up
(Basic Chemicals)
- Sales of melamine (both domestic and export), urea including AdBlue up
Sales of high purity sulfuric acid down, naphtha cost up
- Sales up, OP down
(Total Segment)
$\checkmark$ Sales up $¥ 0.7$ billion, OP flat
<vs. 1H FY2013 Outlook as of May 2013 >
(Fine Chemicals)
- Sales of TEPIC and environmental related products above expectations, sales of Custom Chemicals below expectations
- Sales up, OP down
(Basic Chemicals)
$\checkmark$ Sales of melamine (both domestic and export) and urea including AdBlue above expectations
$\diamond$ Sales of high purity sulfuric acid below expectations, naphtha cost up
$\checkmark$ Sales up, OP down
(Total Segment)
- Sales up $¥ 0.7$ billion, OP down $¥ 0.1$ billion
(Fine Chemicals)
- Fine Chemicals sales in line with expectations, Basic Chemicals sales below expectations
(Blank)


## Performance Materials - (A) Topics

- Advanced Materials Research Lab. (*tentative name)
- Focusing on developing new applications
- To be completed in July 2014 ( $¥ 3.4$ billion capex)
- Integration of R\&D functions for new products and applications of Performance Materials
$\checkmark$ FY2012 capex program of NCK (Korean subsidiary) (approval basis)
<Display Materials>
Expansion of SUNEVER production facilities, warehouses, R\&D center
<Semiconductors Materials>
Expansion of BARC and multi layer process materials production facilities, warehouses
- 100\% Acquisition of Thin Materials AG (TMAT)
<Full Acquisition Date> June 28, 2013
<Location> Munich, Germany (in the premises of Fraunhofer-Gesellschaft, FhG)
<Representative> Dr. Franz Richter
<Purpose of Acquisition>
To adopt TMAT's advanced processing and material development technologies for 3D packaging for semiconductors


## Performance Materials - (B) Display Materials

| <vs. 1H FY2012> | Total Display Materials up 23\% <br> Substantial increase in IPS/FFS, VA and 3D TV materials <br> TN down |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| <vs. 1H FY2013 Outlook All SUNEVER products above expectations <br> as of May 2013> 3D TV materials below expectations |  |  |  |  |  |  |  |
| $\underline{2 H ~ F Y} 2013$ Sales Outlook |  |  |  |  |  |  |  |
| <vs. 2H FY2012> | Total Display Materials up 4\% <br> Substantial increase in IPS/FFS <br> Hole injection layer materials for OLED launching <br> TN, VA and 3D TV materials down |  |  |  |  |  |  |
| <vs. 2H FY2013 as of May 2013> | - IPS/FFS above expectations <br> - TN, VA and 3D TV materials below expectations |  |  |  |  |  |  |
|  | Main Products | Sales YOY Change |  |  |  |  |  |
|  |  | FY2013 Outlook as of Oct 2013 |  |  | FY2013 Outlook as of May 2013 |  |  |
|  |  | 1H | 2H E | Total | 1H E | 2H E | Total |
|  | Total SUNEVER | +24\% | +3\% | +13\% | -2\% | -5\% | -3\% |
|  | Other Display Materials (1) | +1\% | +17\% | +10\% | +28\% | +61\% | +46\% |
|  | Total Display Materials | +23\% | +4\% | +13\% | -1\% | -2\% | -1\% |

(1) NHC(protective coating for touch panels), 3D TV materials, etc

## Performance Materials - (C) Semiconductors Materials

## 1H FY2013 Sales Review

<vs. 1H FY2012>
Total Semiconductors Materials up 9\% (BARC down 4\% :KrF up, ArF down)

- Other Semiconductors Materials (including multi layer process materials) up 103\%
<vs. 1H FY2013 Outlook Total Semiconductors Materials above expectations
as of May 2013>
- BARC below expectations (KrF up, ArF down),
- Other Semiconductors Materials (including multi layer process materials) above expectations

2H FY2013 Sales Outlook
Total Semiconductors Materials up 10\%

- BARC up 3\% (KrF up, ArF up)
$\checkmark$ Other Semiconductors Materials (including multi layer process materials) up 42\%
<vs. 2H FY2013 Outlook as of May 2013>

Total Semiconductors Materials above expectations

- BARC below expectations (KrF in line with expectations, ArF below expectations)
- Other Semiconductors Materials (including multi layer process materials) above expectations

| Main Products | Sales YOY Change |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY2013 Outlook as of Oct 2013 |  |  | FY2013 Outlook as of May 2013 |  |  |
|  | 1H | 2H E | Total | 1H E | 2H E | Total |
| BARC | -4\% | +3\% | +0\% | -3\% | +7\% | +2\% |
| KrF | +2\% | +1\% | +1\% | -3\% | +1\% | -1\% |
| ArF | -5\% | +7\% | +1\% | -1\% | +12\% | +5\% |
| Other Semiconductors Materials (1) | +103\% | +42\% | +67\% | +47\% | +15\% | +28\% |
| Total Semiconductors Materials | +9\% | +10\% | +9\% | +3\% | +8\% | +6\% |

(1) Multi layer process materials, microlens, etc

## Performance Materials - (D) SNOWTEX, Organo sol

## 1H FY2013 Sales Review

$\checkmark$ SNOWTEX : Down (sluggish demand for polishing materials, demand for non-polishing materials up)

- Organo sol : Down due to sluggish demand


## 2H FY2013 Sales Outlook

SNOWTEX : Marketing efforts expected to increase sales for both applications vs. 2H FY2012

- Organo sol : Down due to sluggish demand

Focusing on developing new applications (mainly for mobile materials by improving electronic insulation and decreasing coefficient of thermal expansion)

|  |  |  | Sale | YOY | hang | (1) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Main Products | $\begin{aligned} & \text { FY2 } \\ & \text { as } \end{aligned}$ | $\begin{aligned} & 13 \text { Outl } \\ & \text { f Oct } 20 \end{aligned}$ |  | $\begin{aligned} & \text { FY20 } \\ & \text { as } 0 \end{aligned}$ | 13 Out | $\begin{aligned} & \text { look } \\ & 013 \end{aligned}$ |
|  |  | 1H | 2H E | Total | 1H E | 2H E | Total |
| SNOWTEX | Mainly Used for : <br> (A) polishing materials (silicon wafer, aluminum and glass hard disk), <br> (B) non-polishing materials ( NOx reduction catalyst, automobile catalyst, chrome-free electrical steel sheet) <br> Largest domestic producer | -2\% | +24\% | +10\% | +8\% | +28\% | +17\% |
| Organo sol | - Used for : <br> hard coating materials, electronic information materials <br> World largest producer | -33\% | -8\% | -21\% | -13\% | +6\% | -5\% |

Inorganic Materials in U.S.A.
(1) Non-consolidated basis

- October 1, 2013, Nissan Chemical Houston (NCH) (mainly producing inorganic materials) merged into Nissan Chemical America (NCA) (mainly developing and marketing inorganic materials) to prepare for smooth introduction of SAP ERP systems from April 2014
- NCA's fiscal year change

FY2013 = from January 1, 2013 to March 31, 2014 (15 months) FY2014 = from April 1, 2014 to March 31, 2015 (12 months)
$\diamond$ Asset impairment loss of $¥ 0.3$ billion (extraordinary losses) expected at NCA in 2H FY2013

Performance Materials - (E) Profit Overview
(¥billion)

|  | FY2012 |  |  | FY2013 E <br> as of Oct 2013 |  |  | Change |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | 1H | 2H | Total | 1H | 2H E | Total | 1H | 2H E | Total |
| Sales | 18.8 | 18.6 | 37.4 | 20.6 | 21.9 | 42.5 | 1.8 | 3.3 | 5.1 |


| FY2013 E <br> as of May2013 |  |  | FY2013E <br> as of July2013 |
| :---: | :---: | :---: | :---: |
| 1H E | 2H E | Total | 1H E |
| 19.6 | 20.3 | 39.9 | 20.4 |


| OP | 4.1 | 3.1 | 7.2 | 4.4 | 3.6 | 8.0 | 0.3 | 0.5 | 0.8 |
| :---: | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |


| 3.5 | 3.7 | 7.2 | 3.8 |
| :--- | :--- | :--- | :--- |

## 1H FY2013 Review <br> <vs. 1H FY2012>

- SUNEVER sales up (VA and IPS/FFS up, TN down)
- Total Semiconductors Materials sales up (BARC down, other materials up substantially)
- Sales of SNOWTEX and organo sol down
- Sales up $¥ 1.8$ billion, OP up $¥ 0.3$ billion
<vs. 1H FY2013 Outlook as of May 2013>
- AII SUNEVER products sales above expectations, 3D TV materials below expectations
Total Semiconductors Materials sales above expectations (BARC below expectations, other materials above substantially expectations)
$\checkmark$ Sales of SNOWTEX and organo sol below expectations
- Sales up $¥ 1.0$ billion, OP up $¥ 0.9$ billion
<vs. 1H FY2013 Outlook as of July 2013 >
$\checkmark$ Sales of SUNEVER, BARC, other semiconductors materials above expectations,
Inorganic Materials in line with expectations
$\checkmark$ Sales up $¥ 0.2$ billion, OP up $¥ 0.6$ billion

2H FY2013 Outlook
<vs. 2H FY2012>

- SUNEVER sales up (IPSIFFS up, TN and VA down)
- Total Semiconductors Materials sales up (BARC up, other semiconductors materials up)
- Sales of SNOWTEX up, organo sol down
- Sales up $¥ 3.3$ billion, OP up $¥ 0.5$ billion
<vs. 2H FY2013 Outlook as of May 2013>
$\checkmark$ SUNEVER sales above expectations (IPSIFFS above expectations,
TN and VA below expectations)
- Total Semiconductors Materials sales above expectations (BARC below expectations, other materials above expectations)
$\checkmark$ Inorganic Materials up (NCA's accounting period for this 2H changed from 6 to 9 months, see p26)
$\checkmark$ R\&D expenses up
Sales up $¥ 1.6$ billion, OP down $¥ 0.1$ billion
(Blank)


## Agrochemicals－（A）Sales Distribution（before discount）


－Main Products（in order of FY2012 sales amount）：
ROUNDUP（herbicide），SIRIUS（herbicide），PERMIT（herbicide）， PULSOR（THIFLUZAMIDE，fungicide），TARGA（herbicide）， STARMITE（miticide），LEIMAY（fungicide）， SANMITE（insecticide），ALTAIR（NC－620）（herbicide）

|  | Non－consolidated Sales YOY Change （before discount） |  |
| :---: | :---: | :---: |
|  | $\begin{gathered} \hline \text { FY2012 } \\ \text { IFY2011 } \\ \hline \end{gathered}$ | $\begin{aligned} & \text { FY2013E } \\ & \text { IFY2012 } \end{aligned}$ |
| ROUNDUP |  |  |
| SIRIUS |  |  |
| PERMIT |  |  |
| $\qquad$ |  |  |
| TARGA |  |  |
| STARMITE |  |  |
| LEIMAY |  |  |
| SANMITE |  |  |
| $\begin{gathered} \hline \text { ALTAR } \\ \text { (NC-620) } \\ \hline \end{gathered}$ |  |  |

YOY Change

| ＋0～＋5\％ | $\nearrow$ | －0～－5\％ | $\lambda$ |
| :---: | :---: | :---: | :---: |
| ＋5～＋10\％ | $\nearrow \nearrow$ | －5～－10\％ | い |
| ＋10～＋15\％ | フ17 | －10～－15\％ | い1） |
| ＋15\％～ | ハアイス | －15\％～ | 464t |

## Agrochemicals - (B) Overview

- Stable profit center
- Strengthening product portfolio by: in-house developed products, acquired products,
(launch) (products)
FY2008 LEIMAY (fungicide, in-house) STARMITE (miticide, in-house)
FY2009 PULSOR (THIFLUZAMIDE) (fungicide, acquired from Dow) PREVATHON (insecticide, licensed from DuPont)
FY2010 AVH (herbicide, licensed from ZEN-NOH, Bayer and Hokko) ROUNDUP AL for general household market, growing steadily
FY2011 ALTAIR(NC-620) (paddy rice herbicide, in-house) launched in Korea
FY2012 ALTAIR(NC-620) (paddy rice herbicide, in-house) launched in Japan
FY2013 Bulk shipment of animal health products to licensee started in July (for pets to exterminate tick and flea, licensing product)
FY2014 Animal health products expected to be launched in USA and EU
FY2014-16 Fruits/vegetables/paddy rice insecticide (licensed-in product),
Fruits/vegetables/tea insecticide (licensed-in product),
Fruits/vegetables fungicide (licensed-in product)
FY2019- Insecticide (in-house)
FFull reconstruction of Biological Research Laboratories FY2010-2015 (FY2010-12 $¥ 4.6$ billion capex) (Main completed facilities) Fully automated chemical compounds library, weather simulation room
- Acquired 3\% share of IHARABRÁS (leading agro company in Brazil) in September 2011 to strengthen R\&D and marketing capabilities in the rapidly growing market in Latin America
- Export sales account for about 21\% of FY2013 Outlook non-consolidated segment sales (Asia:44\%, Europe,Africa:37\%, North/Central/South America:19\%)


## Agrochemicals - (C) Non-consolidated Segment Sales (before discount)

|  | Non-consolidated Sales YOY Change (before discount) |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | FY2013 Outlook as of Oct 2013 |  |  | FY2013Outlookas of May 2013 |
|  | 1H | 2H E | FY2013 E |  |
| ROUNDUP | +16\% | +1\% | +6\% | -2\% |
| Except ROUNDUP | +22\% | +3\% | +10\% | +7\% |
| Total Segment | +20\% | +3\% | +9\% | +5\% |


|  | Distribution of NCI <br> Non-consolidated Sales |  |
| :--- | ---: | ---: |
|  | FY2011 | FY2012 |
| Fungicide +Insecticide | $2 \%$ | $3 \%$ |
| Insecticide | $18 \%$ | $18 \%$ |
| Fungicide | $13 \%$ | $13 \%$ |
| Herbicide | $65 \%$ | $64 \%$ |
| Plant grow th regulator | $2 \%$ | $2 \%$ |
| Others | $1 \%$ | $1 \%$ |



Fungicide + Insecticide $11 \%$

- Insecticide

Fungicide 22\%
Herbicide 34\%
Plant growth regulator 2\%
Others
1\%
※2011/10~2012/9

## Agrochemicals - (D) Profit Overview

(¥billion)

|  | FY2012 |  |  | $\begin{gathered} \text { FY2013 E } \\ \text { as of Oct } 2013 \end{gathered}$ |  |  | Change |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1H | 2H | Total | 1H | 2HE | Total | 1H | 2HE | Total |
| Sales | 13.4 | 22.0 | 35.4 | 16.0 | 22.9 | 38.9 | 2.6 | 0.9 | 3.5 |


| OP | 1.3 | 3.7 | 5.0 | 2.4 | 3.8 | 6.2 | 1.1 | 0.1 | 1.2 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## 1H FY 2013 Review <br> <vs. 1H FY2012>

- In domestic market, sales of ROUNDUP (both ML and AL) and ALTAIR up
- Export up (mainly TARGA)
- In July, bulk shipment of the animal health product to the licensee started as scheduled
- Fixed cost up (depreciation cost of the ALTAIR plant, R\&D expenses up due to accelerated pipeline development)
- Sales up $¥ 2.6$ billion, OP up $¥ 1.1$ billion
<vs. 1H FY2013 Outlook as of May 2013>
- In domestic market, sales of ROUNDUP above expectations
- Export above expectations
(mainly PULSOR, TARGA, STARMITE)
- Sales up $¥ 2.6$ billion, OP up $¥ 1.0$ billion
<vs. 1H FY2013 Outlook as of July 2013>
- In domestic market, sales of ROUNDUP above expectations
- Sales up $¥ 1.5$ billion, OP up $¥ 0.7$ billion

| FY2013 E <br> as of May2013 |  | FY2013E <br> as of July2013 |  |
| :---: | :---: | :---: | :---: |
| 1H E | 2H E | Total | 1H E |
| 13.4 | 22.8 | 36.2 | 14.5 |



## 2H FY 2013 Outlook <br> <vs. 2H FY2012>

- In domestic market, sales of ALTAIR up
- Export up (mainly PERMIT, PULSOR, SANMITE, ALTAIR)
- Fixed cost up (depreciation cost of the ALTAIR plant,

R\&D expenses up due to accelerated pipeline development)
-Sales up $¥ 0.9$ billion, OP up $¥ 0.1$ billion

## <vs. 2H FY2013 Outlook as of May 2013>

- In domestic market, sales of ROUNDUP and ALTAIR above expectations
- Export above expectations (mainly PERMIT)
- Sales up $¥ 0.1$ billion, OP in line with expectations


## Pharmaceuticals - (A) NCI Business Model

- Steadily expanding segment in mid-term perspective
- Unique ethical pharma business model without sales force


API*: Active Pharmaceutical Ingredient

## Pharmaceuticals - (B) LIVALO (anti-cholesterol drug)

-Domestic market share up steadily (about20\% in FY2012)

- New plant completed in March 2011, commercial production started in May 2012
-Full reconstruction of Biological Research Laboratories (FY2010-2015)
- January - February 2013, crystalline form patents approved

August 2013, domestic compound patent expired

- October 2013, Custom Chemicals (Custom manufacturing and process researching services for pharma from pre-clinical testing to commercial production stages) transferred from Chemical Segment to Pharma Segment (segment reporting to be changed from 3Q FY2013) to seek synergy of the two divisions

|  | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 E |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | $\begin{gathered} \text { As of May } \\ 2013 \end{gathered}$ | $\begin{gathered} \text { As of Oct } \\ 2013 \end{gathered}$ |
| Domestic End Market Sales <br> (NHI drug price, $¥$ billion) | 41.3 | 45.2 | 50.5 | 51.5 | 53.0 | 53.0 |
| Market Share (\%) | 14\% | 15\% | 17\% | 20\% | 20\% | 21\% |
| Our Domestic and Export Sales (¥billion) | 7.7 | 8.2 | 8.9 | 10.4 | 10.0 | 10.0 |

FY2012
Market share
Crestor 34\%
Lipitor 27\%
LIVALO 20\%
Mevalotin 12\%

## Pharmaceuticals - (C) LIVALO World Wide Strategy \& Pipeline

## LIVALO World Wide Strategy

| Country/Region | Developing Status | Launch (schedule) | Business Partner |
| :---: | :---: | :---: | :---: |
| Japan | Launched | Sep 2003 | Kow a, Daiichi-Sankyo (1) |
| Korea | Launched | Jul 2005 | JWP Pharmaceutical |
| Thailand | Launched | Jan 2008 | Biopharm-Chemical |
| China | Launched | Jul 2009 | Kowa Shanghai |
| USA | Launched | Jun 2010 | Kow a(KPA) (2) |
| Lebanon | Launched | Mar 2011 | Algorithm |
| Spain | Launched | May 2011 | Recordati, Esteve |
| Portugal | Launched | Jun 2011 | Recordati, Delta |
| Mexico | Launched | Feb 2012 | Eli Lilly |
| Indonesia | Launched | May 2012 | Indonesia Tanabe |
| Taiw an | Launched | Jun 2012 | Taiw an Tanabe |
| Switzerland | Launched | Jan 2013 | Ei Lilly |
| Ukraine | Launched | May 2013 | Recordati |
| Brazil | Launched | Sep 2013 | Eli Lilly |
| France | Approved | 2013 | Recordati |
| Italy | Approved | 2013 | Recordati |

Other approved countries: Australia, Cyprus, Greece, Ireland, Turkey, Venezuela etc.
(1) As of July 2013, Kowa was the sole partner (2) As of July 2013, Eli Lilly was the sole partner

Pipeline

| Product |  | arket | Developing Status | Licensee | Expected Market Size ( $¥$ billion) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| NT-702 | Japan | Intermittent claudication | Phase II | Taisho | 20-30 |
|  |  | Asthma |  |  | 20 |
| NTC-801 <br> (Antiarrhythmic agent) | Japan |  | Discontinuation of clinical development No further plans for development at this time (under discussion among three companies) | Teijin | 1 million patients (2015) |
|  | World wide (except Japan) |  |  | BMS | 8.4 million patients (2015) |
| NIP-022 (Platelet generating stimulator agent) |  |  | Phase I | Ono | 0.35 million patients (2015 in Japan) |

Pharmaceuticals - (D) Profit Overview

|  | FY2012 |  |  | FY2013 E as of Oct 2013 |  |  | Change |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1H | 2H | Total | 1H | 2HE | Total | 1H | 2HE | Total |
| Sales | 5.3 | 5.3 | 10.6 | 5.7 | 4.4 | 10.1 | 0.4 | -0.9 | -0.5 |


| OP | 2.6 | 2.6 | 5.2 | 3.1 | 2.0 | 5.1 | 0.5 | -0.6 | -0.1 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## 1H FY2013 Review <br> <vs. 1H FY2012>

- LIVALO

Domestic sales volume up
Variable cost down by new plant

- No milestones
- Sales up $¥ 0.4$ billion, OP up $¥ 0.5$ billion
<vs. 1H FY2013 Outlook as of May 2013>
- Export LIVALO sales above expectations
- Sales up $¥ 0.1$ billion, OP up $¥ 0.2$ billion
<vs. 1H FY2013 Outlook as of July 2013>
- Sales in line with expectations, OP up $¥ 0.1$ billion
(¥billion)

| FY2013 E <br> as of May2013 |  | FY2013 E <br> as of July 2013 |  |
| ---: | ---: | ---: | :---: |
| 1H E | 2H E | Total | 1HE |
| 5.6 | 4.5 | 10.1 | 5.7 |


| 2.9 | 2.0 | 4.9 | 3.0 |
| :--- | :--- | :--- | :--- |

## 2H FY2013 Outlook <br> <vs. 2H FY2012>

- Domestic LIVALO sales down due to expiration of domestic compound patent in August 2013
- Export LIVALO sales down

Sales down $¥ 0.9$ billion, OP down $¥ 0.6$ billion
<vs. 2H FY2013 Outlook as of May 2013>

- Domestic LIVALO sales above expectations
- Export LIVALO sales below expectations

Sales down $¥ 0.1$ billion, OP flat

## Trading - Profit Overview

Mainly import raw and intermediate materials and export products for NCl group
(¥billion)

|  | FY2012 |  |  | FY2013 E <br>  <br>  <br>  |  |  | 1H Oct | 2H |  |  | Change |  |  |
| :---: | :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: | :---: | :---: |
| Sales | 22.7 | 23.9 | 46.6 | 24.5 | 25.2 | 49.7 | 1.8 | 1.3 | 3.1 |  |  |  |  |


| FY2013E <br> as of May2013 |  | FY2013E <br> as of July2013 |  |
| :---: | :---: | :---: | :---: |
| 1HE | 2H E | Total | 1HE |
| 23.7 | 25.0 | 48.7 | 23.7 |


| OP | 0.7 | 0.7 | 1.4 | 0.7 | 0.7 | 1.4 | 0.0 | 0.0 | 0.0 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |


| 0.6 | 0.8 | 1.4 | 0.6 |
| :--- | :--- | :--- | :--- |

## 1H FY 2013 Review <br> <vs. 1H FY2012>

Sales up due to increase in trading volume
related to agrochemicals and electronic materials

- Sales up $¥ 1.8$ billion, OP flat


## <vs. 1H FY2013 Outlook as of May 2013>

- Trading volume related to agrochemicals and electronic materials above expectations
$\checkmark$ Sales up $¥ 0.8$ billion, OP up $¥ 0.1$ billion
<vs. 1H FY2013 Outlook as of July 2013>
- Sales up $¥ 0.8$ billion, OP up $¥ 0.1$ billion

2H FY 2013 Outlook
<vs. 2H FY2012>
$\checkmark$ Trading volume up
Sales up $¥ 1.3$ billion, OP flat
<vs. 2H FY2013 Outlook as of May 2013>

- Trading volume above expectations

Sales up $¥ 0.2$ billion, OP flat
(Blank)

## Capex/Depreciation/R\&D by Segment

(¥billion)

|  | Capex(1) |  |  |  |  | Depreciation(2) |  |  |  |  | R\&D expenses |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2009 | 2010 | 2011 | 2012 | 2013E | 2009 | 2010 | 2011 | 2012 | 2013E | 2009 | 2010 | 2011 | 2012 | 2013E | \% of Sales |
| Chem |  | 1.9 | 1.6 | 1.0 | 1.2 |  | 3.4 | 2.5 | 2.0 | 1.8 |  | 0.8 | 0.8 | 0.7 | 0.7 | 1.9\% |
| Performance M. | - | 3.7 | 2.2 | 3.1 | 3.6 |  | 4.1 | 4.3 | 3.7 | 3.3 |  | 5.6 | 6.2 | 6.5 | 6.5 | 15.3\% |
| Agro | - | 0.4 | 2.1 | 2.5 | 1.0 |  | 1.9 | 1.8 | 1.9 | 2.1 |  | 2.6 | 2.8 | 3.0 | 3.5 | 9.0\% |
| Pharma | - | 2.4 | 1.7 | 0.7 | 0.3 | - | 0.3 | 1.0 | 1.1 | 0.9 |  | 2.4 | 2.5 | 2.3 | 2.3 | 22.8\% |
| Trading | - | 0.2 | 0.1 | 0.0 | 0.1 | - | 0.1 | 0.1 | 0.1 | 0.1 |  | 0.0 | 0.0 | 0.0 | 0.0 | 0.0\% |
| Others | - | 1.0 | 0.6 | 0.8 | 0.9 |  | 0.6 | 0.8 | 0.7 | 0.4 |  | 1.2 | 1.3 | 1.2 | 1.2 |  |
| Total | 10.1 | 9.6 | 8.3 | 8.1 | 7.1 | 11.0 | 10.4 | 10.5 | 9.5 | 8.6 | 13.1 | 12.6 | 13.6 | 13.7 | 14.2 |  |
| Capex |  |  |  |  |  |  | \& exp | pense | slSale | s (\%) | 8.8\% | 8.2\% | 9.2\% | 8.9\% | 8.7\% |  |

Actual - Acceptance basis
Outlook - Production commencement basis

## (2) Depreciation Method

SUNEVER, BARC- 4 year declining balance method (50.0\% of initial capex amount in the $1^{\text {st }}$ year) Other products - 8 year declining balance method ( $25.0 \%$ of initial capex amount in the $1^{\text {st }}$ year)

| R\&D Personnel (Sept. 2013) -(1) | 413 |
| :--- | ---: |
| Total Professionals (Sept. 2013) -(2) | 1,036 |
| (1)/(2) | $40 \%$ |

※Parent company only

## FY2012 and 2013 Main Capex Items (Approval basis)

(¥billion)

| FY2012 | FY2013 E <br> as of Oct 2013 |  |  |
| :--- | ---: | :--- | :---: |
| High purity ammonia | 0.3 | Chemical Research Lab. <br> (Instruments) | 0.8 |
| SUNEVER(NCK) | 1.4 | Electronic Materials Lab. <br> (Instruments) | 0.8 |
| BARC(NCK) | 1.2 | Biological Research Lab. | 0.3 |
| Advanced Materials <br> Research Lab. (Building) | 3.4 | Biological Research Lab. <br> (Instruments) | 0.3 |
| Electronic Materials Lab. <br> (Instruments) | 0.8 |  |  |
| Biological Research Lab. | 0.9 |  |  |

NCK=Korean sublidiary

## Financial Strategy - (A) Purchase of Treasury Shares

- Started purchase of treasury shares in 2006 to enhance ROE
- Purchased $¥ 25.5$ billion, 22.8 million shares ( $\mathbf{1 2 . 2 \%}$ of shares issued) in total
- Cancelled all purchased shares


## Record of purchase of treasury shares FY2006-12

|  | FY2006 | FY2007 | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | $\begin{gathered} \hline \text { FY2006- } \\ \text { FY2012 } \\ \text { Total } \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shares purchased (thousand shares) | 3,500 | 3,399 | 7,355 | 0 | 2,167 | 0 | 6,372 | 22,793 |
| Purchase costs ( $¥$ billion) | 4.7 | 5.0 | 8.0 | 0 | 2.8 | 0 | 5.0 | 25.5 |
| Shares cancelled (thousand shares) | 3,000 | 3,635 | 7,000 | 0 | 3,000 | 0 | 6,000 | 22,635 |
| Shares issued at FY end (thousand shares) | 184,635 | 181,000 | 174,000 | 174,000 | 171,000 | 171,000 | 165,000 |  |
| Treasury share at FY end (thousand shares) | 1,367 | 1,233 | 1,660 | 1,709 | 885 | 886 | 1,258 |  |
| Dividend ( $¥$ billion) | 3.7 | 3.6 | 3.8 | 4.2 | 4.1 | 4.1 | 4.3 |  |
| Dividend ( $¥$ I Share) | 20 | 20 | 22 | 24 | 24 | 24 | 26 |  |
| Total payout ratio <br> (dividend + purchase of treasury shares) | 61 | 56 | 117 | 32 | 53 | 37 | 67 |  |

## Financial Strategy - (B) Cash Management Policy

- Aiming to control cash balance around the level of $=$
(Minimum required level
$+$
1/3 of annual scheduled long-term borrowings repayment $+$
1/3 of short-term borrowings outstanding
$+$
Contingent risk reserves (added for FY2011)
(non-consolidated basis) <br> \title{
Mid-term Business Plan Vista 2015 Stage II (FY2013-2015) <br> \title{
Mid-term Business Plan Vista 2015 Stage II (FY2013-2015) (A) Financial Targets
} (A) Financial Targets
}

|  | ( $¥$ billion) |  |
| :--- | ---: | ---: |
| 1. PL | FY2012 | FY2015 |
| Sales | 153.8 | 180.0 |
| Operating Profit | 19.5 | 26.0 |
| Ordinary Income | 20.5 | 26.5 |
| Net Income | 13.9 | 18.5 |
| EPS( $¥$ ) | 84.00 | 113.00 |


| 2. Segment |  |  |  | (\#billion) |
| :---: | :---: | :---: | :---: | :---: |
|  | Sales |  | Operating Profit |  |
|  | FY2012 | FY2015 | FY2012 | FY2015 |
| Chemicals and others (1) | 70.4 | 77.5 | 2.1 | 3.6 |
| Performance Materials | 37.4 | 53.8 | 7.2 | 11.3 |
| Agro | 35.4 | 40.8 | 5.0 | 7.6 |
| Pharma | 10.6 | 7.9 | 5.2 | 3.5 |
| Total | 153.8 | 180.0 | 19.5 | 26.0 |

(1) "Chemicals and others" including Chemicals segment, Trading segment, Others segment and Adjustment

# Mid-term Business Plan Vista 2015 Stage II (FY2013-2015) 

 (B) Financial IndicatorsHighest importance on ROE as well as OP margin
ROE : FY2015 Target 13.4\%
OP margin : FY2015 Target 14.4\%

- Dividend payout ratio above 30\%
- In addition, continue to purchase treasury shares timely
- Maintain R\&D expenses/sales above 9\%


## Long-term Financial Performance Trend



## Long Term Financial Performance Trend

( $¥$ billion)

|  | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | 155.9 | 161.4 | 169.1 | 174.4 | 169.2 | 160.2 | 149.0 | 154.2 | 148.6 | 153.8 |
| Operating Profit | 15.7 | 17.3 | 21.7 | 20.8 | 24.8 | 17.4 | 19.2 | 19.8 | 15.5 | 19.5 |
| Ordinary Income | 14.6 | 17.4 | 21.3 | 21.2 | 24.4 | 16.9 | 19.2 | 19.4 | 15.9 | 20.5 |
| Net Income | 8.7 | 11.3 | 13.7 | 14.0 | 15.5 | 10.1 | 12.8 | 13.0 | 11.0 | 13.9 |
| EBITDA | 26.1 | 26.9 | 31.6 | 30.5 | 34.5 | 27.6 | 30.1 | 30.2 | 25.9 | 29.0 |
| OP Margin | 10.0\% | 10.7\% | 12.8\% | 12.0\% | 14.6\% | 10.9\% | 12.8\% | 12.9\% | 10.4\% | 12.7\% |
| ROE(\%) | 13.4\% | 15.2\% | 16.1\% | 14.7\% | 15.6\% | 10.3\% | 12.6\% | 11.9\% | 9.5\% | 11.4\% |
| EPS(\#) | 46.21 | 59.77 | 72.73 | 75.43 | 85.15 | 57.26 | 74.00 | 75.94 | 64.52 | 83.74 |
| Dividend(¥/share) | 11 | 11 | 15 | 20 | 20 | 22 | 24 | 24 | 24 | 26 |
| Purchase of treasury shares | - | - | - | 4.7 | 5.0 | 8.0 | - | 2.8 | - | 5.0 |
| Net Assets | 69.2 | 78.5 | 92.0 | 98.1 | 100.1 | 95.7 | 106.5 | 112.4 | 119.6 | 126.7 |
| Cash | 5.9 | 4.3 | 8.5 | 11.0 | 7.6 | 9.7 | 14.8 | 21.1 | 27.9 | 31.9 |
| Liabilities with interest | 57.4 | 44.6 | 41.5 | 32.4 | 34.4 | 45.5 | 42.1 | 39.9 | 38.9 | 38.1 |
| D/E ratio (1) | 78.0\% | 53.7\% | 38.5\% | 23.2\% | 27.2\% | 37.1\% | 26.0\% | 16.9\% | 9.3\% | 5.0\% |
| Equity ratio | 40.1\% | 46.4\% | 50.2\% | 55.3\% | 58.0\% | 55.5\% | 58.7\% | 60.7\% | 62.4\% | 63.0\% |
| Capex | 6.6 | 6.6 | 9.2 | 12.1 | 10.9 | 13.9 | 10.1 | 9.6 | 8.3 | 8.1 |
| Depreciation | 10.4 | 9.6 | 9.9 | 9.7 | 9.7 | 10.2 | 11.0 | 10.4 | 10.5 | 9.5 |
| R\&D Expenses | 8.7 | 8.6 | 9.2 | 9.9 | 12.5 | 13.7 | 13.1 | 12.6 | 13.6 | 13.7 |
| R\&D Expenses/Sales(\%) | 5.6\% | 5.3\% | 5.4\% | 5.7\% | 7.4\% | 8.6\% | 8.8\% | 8.2\% | 9.2\% | 8.9\% |
| Number of employees (parent company) | 1,505 | 1,502 | 1,502 | 1,558 | 1,614 | 1,657 | 1,710 | 1,750 | 1,730 | 1,726 |

(1) D/E ratio = (Borrowings - Cash ) / Shareholders' equity (\%)

## Sales and Operating Profit by New Segmentation

|  |  | FY2010 | FY2011 | FY2012 | FY2013E |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { の } \\ & \text { D } \\ & \text { O } \\ & \text { © } \end{aligned}$ | Chemicals | 38.1 24.7\% | 36.9 24.8\% | 36.6 23.8\% | 37.8 | 23.3\% |
|  | Performance M | 38.0 24.6\% | $34.0 \quad 22.9 \%$ | 37.4 24.3\% | 42.5 | 26.2\% |
|  | Agro | 34.4 22.3\% | $33.8 \quad 22.7 \%$ | 35.4 23.0\% | 38.9 | 23.9\% |
|  | Pharma | 9.6 6.2\% | 10.0 6.7\% | 10.6 6.9\% | 10.1 | 6.2\% |
|  | Trading | 44.1 28.6\% | 44.8 30.1\% | 46.6 30.3\% | 49.7 | 30.6\% |
|  | Others | 27.0 17.5\% | 20.0 13.5\% | 21.2 13.8\% | 21.0 | 12.9\% |
|  | Adjustment | -37.0-24.0\% | -30.9-20.8\% | -34.0-22.1\% | -37.5 | -23.1\% |
|  | Total | 154.2 100\% | 148.6 100\% | 153.8 100\% | 162.5 | 100\% |


| $\begin{aligned} & \text { O } \\ & \text { ण } \\ & \text { © } \end{aligned}$ | Chemicals | 2.4 12.1\% | 1.6 10.3\% | 1.9 9.7\% | 2.4 | 10.9\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Performance M. | 7.9 39.9\% | 4.8 31.0\% | 7.2 36.9\% | 8.0 | 36.4\% |
|  | Agro | 4.8 24.2\% | 4.4 28.4\% | $5.0 \quad 25.6 \%$ | 6.2 | 28.2\% |
|  | Pharma | 4.4 22.2\% | 4.6 29.7\% | $5.2 \quad 26.7 \%$ | 5.1 | 23.2\% |
|  | Trading | 1.4 7.1\% | 1.3 8.4\% | 1.4 7.2\% | 1.4 | 6.4\% |
|  | Others | 1.0 5.1\% | 0.3 1.9\% | 0.7 3.6\% | 0.7 | 3.2\% |
|  | Adjustment | -2.1-10.6\% | -1.5 -9.7\% | -1.9 $-9.7 \%$ | -1.8 | -8.2\% |
|  | Total | 19.8 100\% | 15.5 100\% | 19.5 100\% | 22.0 | 100\% |


|  |  | FY2011 | FY2012 |  |
| :---: | :---: | :---: | :---: | :---: |
| $\cdots$ | Chemicals | $31.6 \quad 16.6 \%$ | 30.3 | 15.2\% |
| ¢ | Performance M. | 31.5 16.6\% | 34.3 | 17.2\% |
| (1) | Agro | 44.6 23.5\% | 46.7 | 23.4\% |
| $\stackrel{\square}{\square}$ | Pharma | 12.4 6.5\% | 11.3 | 5.7\% |
| - | Trading | 16.5 8.7\% | 17.3 | 8.7\% |
| - | Others | 9.5 5.0\% | 9.2 | 4.6\% |
| ¢ | Common Assets | 44.0 23.1\% | 50.1 | 25.2\% |
| - | Total | 190.1 100\% | 199.2 | 100\% |


|  | Chemicals | 6.3\% | 4.3\% | 5.2\% | 6.3\% |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Performance M. | 20.8\% | 14.1\% | 19.3\% | 18.8\% |
|  | Agro | 14.0\% | 13.0\% | 14.1\% | 15.9\% |
|  | Pharma | 45.8\% | 46.0\% | 49.1\% | 50.5\% |
|  | Trading | 3.2\% | 2.9\% | 3.0\% | 2.8\% |
|  | Others | 3.7\% | 1.5\% | 3.3\% | 3.3\% |
|  | Total | 12.9\% | 10.4\% | 12.7\% | 13.5\% |


|  | Chemicals | 5.0\% | 6.3\% |
| :---: | :---: | :---: | :---: |
|  | Performance M. | 15.2\% | 20.9\% |
|  | Agro | 9.9\% | 10.8\% |
|  | Pharma | 37.1\% | 46.4\% |
|  | Trading | 7.9\% | 7.8\% |
|  | Others | 3.2\% | 7.5\% |
|  | Total | 8.1\% | 9.8\% |

## Pro Forma Sales and Operating Profit by Former Segmentation(1)

( $¥$ billion)

|  |  | FY2005 | FY2006 | FY2007 | FY2008 | FY2009 | FY2010 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Chemicals | 50.2 29.7\% | 55.2 31.6\% | 60.7 35.9\% | 55.4 34.6\% | 46.1 30.9\% | 49.6 32.2\% |
|  | Electronic Materials | 23.4 13.9\% | 22.8 13.1\% | 28.1 16.6\% | 23.2 14.5\% | 26.6 17.9\% | 26.2 17.0\% |
|  | Agrochemicals | 35.8 21.1\% | 33.5 19.2\% | 33.2 19.6\% | 35.4 22.1\% | 33.8 22.7\% | 34.4 22.3\% |
|  | Pharm aceuticals | 5.1 3.0\% | $6.5 \quad 3.7 \%$ | 8.1 4.8\% | 9.2 5.7\% | $9.5 \quad 6.4 \%$ | 9.6 6.2\% |
|  | Trading | 35.7 21.1\% | 40.4 23.2\% | 47.0 27.8\% | 46.3 28.9\% | 41.3 27.7\% | 44.1 28.6\% |
|  | Others (2) | 53.4 31.6\% | 53.4 30.6\% | 28.0 16.5\% | 28.4 17.7\% | 27.4 18.4\% | $27.0 \quad 17.5 \%$ |
|  | Adjustment | -34.4 -20.3\% | -37.4 -21.4\% | -35.9-21.2\% | -37.7-23.5\% | -35.7 -24.0\% | -36.7-23.8\% |
|  | Total | 169.2 100\% | 174.4 100\% | 169.2 100\% | 160.2 100\% | $149.0 \quad 100 \%$ | 154.2 100\% |
| $0$ | Chemicals | 4.6 21.3\% | 5.4 25.8\% | 6.3 25.4\% | 3.6 20.7\% | 2.6 13.5\% | 4.1 20.7\% |
|  | Electronic Materials | 11.1 51.3\% | 9.4 45.0\% | 10.3 41.5\% | 4.9 28.2\% | 7.3 38.0\% | 6.2 31.3\% |
|  | Agrochemicals | 3.7 17.2\% | 3.5 16.7\% | 4.1 16.5\% | $5.0 \quad 28.7 \%$ | 4.7 24.5\% | 4.8 24.2\% |
|  | Pharm aceuticals | 1.2 5.6\% | 2.1 10.0\% | 3.9 15.7\% | $4.5 \quad 25.9 \%$ | 4.6 24.0\% | $4.4 \quad 22.2 \%$ |
|  | Trading | 0.8 3.8\% | 1.0 4.6\% | $1.0 \quad 4.0 \%$ | 1.1 6.3\% | 1.1 5.7\% | 1.4 7.1\% |
|  | Others | 0.9 4.1\% | 1.1 5.4\% | 0.8 3.2\% | 0.7 4.0\% | $1.0 \quad 5.2 \%$ | 1.0 5.1\% |
|  | Adjustment | -0.7 $-3.3 \%$ | -1.6 $-7.4 \%$ | -1.6 -6.3\% | -2.4-13.8\% | -2.1-10.9\% | -2.1-10.6\% |
|  | Total | 21.7 100\% | 20.8 100\% | 24.8 100\% | 17.4 100\% | 19.2 100\% | 19.8 100\% |
| $\begin{aligned} & 0 \\ & 0 \\ & 3 \\ & 3 \\ & \text { 를 } \\ & \text { 은 } \end{aligned}$ | Chemicals | 9.2\% | 9.8\% | 10.3\% | 6.5\% | 5.6\% | 8.3\% |
|  | Electronic Materials | 47.4\% | 41.1\% | 36.8\% | 21.0\% | 27.4\% | 23.7\% |
|  | Agrochemicals | 10.4\% | 10.4\% | 12.3\% | 14.0\% | 13.9\% | 14.0\% |
|  | Pharm aceuticals | 24.0\% | 32.2\% | 48.0\% | 49.5\% | 48.4\% | 45.8\% |
|  | Trading | 2.3\% | 2.4\% | 2.2\% | 2.4\% | 2.7\% | 3.2\% |
|  | Others | 1.7\% | 2.1\% | 2.7\% | 2.5\% | 3.6\% | 3.7\% |
|  | Total | 12.8\% | 11.9\% | 14.6\% | 10.9\% | 12.8\% | 12.9\% |

(1) FY2005-2008 are restated based on new segmentation
(2) Sales of Others decreased in FY2007 mainly due to spin-off of Nissan Agri (currently "Sun Agro", fertilizer company, FY2006 sales $¥ 27.7$ billion)

FY2011- 2Q FY2013 Quarterly Sales by Segment
( $¥$ billion)

|  | FY2011 |  |  |  |  | FY2012 |  |  |  |  | FY2013 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | Total | 1Q | 2Q | 3Q | 4Q | Total | 1Q | 2Q |
| Chem | 9.4 | 9.2 | 9.0 | 9.3 | 36.9 | 9.1 | 8.8 | 8.9 | 9.8 | 36.6 | 9.5 | 9.1 |
| Fine Chemicals | 3.0 | 2.9 | 2.4 | 2.6 | 10.9 | 2.9 | 2.7 | 2.4 | 3.2 | 11.2 | 2.9 | 3.1 |
| Basic Chemicals | 6.4 | 6.3 | 6.6 | 6.7 | 26.0 | 6.2 | 6.1 | 6.5 | 6.6 | 25.4 | 6.6 | 6.0 |
| Performance Materials | 8.7 | 8.3 | 8.6 | 8.4 | 34.0 | 9.5 | 9.3 | 9.5 | 9.1 | 37.4 | 10.3 | 10.3 |
| Agro | 7.1 | 5.4 | 3.7 | 17.6 | 33.8 | 8.3 | 5.1 | 4.6 | 17.4 | 35.4 | 9.9 | 6.1 |
| Pharma | 2.9 | 2.3 | 2.4 | 2.4 | 10.0 | 3.5 | 1.8 | 3.1 | 2.2 | 10.6 | 2.9 | 2.8 |
| Trading | 11.6 | 10.9 | 10.8 | 11.5 | 44.8 | 11.9 | 10.8 | 12.5 | 11.4 | 46.6 | 12.7 | 11.8 |
| Others | 4.6 | 4.7 | 4.3 | 6.4 | 20.0 | 3.9 | 6.3 | 4.6 | 6.4 | 21.2 | 4.6 | 5.1 |
| Adjustment | -7.7 | -7.6 | -7.3 | -8.3 | -30.9 | -7.8 | -9.4 | -8.6 | -8.2 | -34.0 | -9.7 | -9.0 |
| Total | 36.6 | 33.2 | 31.5 | 47.3 | 148.6 | 38.4 | 32.7 | 34.6 | 48.1 | 153.8 | 40.2 | 36.2 |

## FY2011- 2Q FY2013 Quarterly OP by Segment

( $¥$ billion)

|  | FY2011 |  |  |  |  | FY2012 |  |  |  |  | FY2013 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | Total | 1Q | 2Q | 3Q | 4Q | Total | 1Q | 2Q |
| Chem | 1.0 | -0.2 | 0.6 | 0.2 | 1.6 | 0.8 | 0.0 | 0.4 | 0.7 | 1.9 | 0.8 | 0.0 |
| Performance Materials | 1.7 | 0.9 | 1.1 | 1.1 | 4.8 | 2.1 | 2.0 | 1.6 | 1.5 | 7.2 | 2.1 | 2.3 |
| Agro | 1.2 | -0.4 | -1.5 | 5.1 | 4.4 | 1.6 | -0.3 | -1.1 | 4.8 | 5.0 | 2.3 | 0.1 |
| Pharma | 1.4 | 1.2 | 1.0 | 1.0 | 4.6 | 1.9 | 0.7 | 1.6 | 1.0 | 5.2 | 1.6 | 1.5 |
| Trading | 0.4 | 0.3 | 0.3 | 0.3 | 1.3 | 0.4 | 0.3 | 0.4 | 0.3 | 1.4 | 0.4 | 0.3 |
| Others | 0.0 | 0.0 | -0.1 | 0.4 | 0.3 | -0.1 | 0.2 | 0.1 | 0.5 | 0.7 | 0.1 | 0.1 |
| Adjustment | -0.5 | -0.4 | -0.4 | -0.2 | -1.5 | -0.4 | -0.6 | -0.5 | -0.4 | -1.9 | -0.6 | -0.4 |
| Total | 5.2 | 1.4 | 1.0 | 7.9 | 15.5 | 6.3 | 2.3 | 2.5 | 8.4 | 19.5 | 6.7 | 3.9 |
| OP Margin | 14.3\% | 4.0\% | 3.4\% | 16.6\% | 10.4\% | 16.5\% | 6.8\% | 7.5\% | 17.4\% | 12.7\% | 16.7\% | 10.6\% |

## FY2009-10 Quarterly Sales by Segment

## (Former Segmentation)

(¥billion)

|  | FY2009 |  |  |  |  | FY2010 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | Total | 1Q | 2Q | 3Q | 4Q | Total |
| Chem | 11.3 | 10.8 | 12.0 | 12.0 | 46.1 | 12.7 | 11.8 | 12.4 | 12.7 | 49.6 |
| Organic/Inorganic Materials | 4.5 | 4.5 | 5.0 | 5.2 | 19.2 | 5.4 | 5.0 | 4.8 | 5.1 | 20.3 |
| Basic Chemicals | 6.8 | 6.3 | 7.0 | 6.8 | 26.9 | 7.3 | 6.8 | 7.6 | 7.6 | 29.3 |
| Electronic Materials | 6.4 | 6.8 | 6.8 | 6.6 | 26.6 | 7.3 | 6.4 | 6.3 | 6.2 | 26.2 |
| Agro | 8.0 | 3.7 | 3.7 | 18.4 | 33.8 | 6.9 | 5.1 | 4.4 | 18.0 | 34.4 |
| Pharma | 2.2 | 2.8 | 2.9 | 1.6 | 9.5 | 2.5 | 2.3 | 2.1 | 2.7 | 9.6 |
| Trading | 10.3 | 9.8 | 10.4 | 10.8 | 41.3 | 10.7 | 10.5 | 11.8 | 11.1 | 44.1 |
| Others | 8.2 | 5.1 | 7.0 | 7.1 | 27.4 | 6.5 | 4.6 | 4.3 | 11.6 | 27.0 |
| Adjustment | -11.1 | -7.5 | -9.1 | -8.0 | -35.7 | -7.6 | -7.6 | -8.6 | -12.9 | -36.7 |
| Total | 35.3 | 31.5 | 33.7 | 48.5 | 149.0 | 39.0 | 33.1 | 32.7 | 49.4 | 154.2 |

## FY2009-10 Quarterly OP by Segment

## (Former Segmentation)

(¥billion)

|  |  |  |  |  |  | FY2009 |  |  |  |  |  | FY2010 |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | Total | 1Q | 2Q | 3Q | 4Q | Total |  |  |  |  |  |
| Chem | 1.2 | -0.7 | 1.0 | 1.1 | 2.6 | 1.6 | 0.2 | 1.1 | 1.2 | 4.1 |  |  |  |  |  |
| Electronic Materials | 2.1 | 2.6 | 1.3 | 1.3 | 7.3 | 2.1 | 1.7 | 1.4 | 1.0 | 6.2 |  |  |  |  |  |
| Agro | 1.0 | -0.7 | -1.3 | 5.7 | 4.7 | 0.8 | 0.0 | -1.3 | 5.3 | 4.8 |  |  |  |  |  |
| Pharma | 1.2 | 1.5 | 1.5 | 0.4 | 4.6 | 1.2 | 0.9 | 1.0 | 1.3 | 4.4 |  |  |  |  |  |
| Trading | 0.2 | 0.3 | 0.3 | 0.3 | 1.1 | 0.4 | 0.3 | 0.4 | 0.3 | 1.4 |  |  |  |  |  |
| Others | 0.5 | -0.1 | 0.2 | 0.4 | 1.0 | 0.1 | 0.0 | -0.1 | 1.0 | 1.0 |  |  |  |  |  |
| Adjustment | -0.9 | -0.4 | -0.6 | -0.2 | -2.1 | -0.4 | -0.6 | -0.3 | -0.8 | -2.1 |  |  |  |  |  |
| Total | 5.3 | 2.5 | 2.4 | 9.0 | 19.2 | 5.8 | 2.5 | 2.2 | 9.3 | 19.8 |  |  |  |  |  |

## Main Products by Segment (New Segmentation)

| Segment | Products | Main Applications |
| :---: | :---: | :---: |
| Chem | Fine Chemicals TEPIC Melamine cyanurate Environmetal product Custom Chemicals | epoxy compound for LED sealants, solder resist, painting <br> flame retardant <br> HI-LITE (chlorinated isocyanuric acid for sterilizing) <br> custom manufacturing and process services for pharmaceutical companies |
|  | Basic Chemicals <br> Melamine <br> AdBlue <br> Ammonia, Sulfuric acid, Nitric acid Highpurity chemicals | adhesive agent for plywood solution of urea in demineralised water for diesel trucks to reduce NOX agents used for cleaning semiconductors |
| Performance Materials | Electronic Materials <br> SUNEVER <br> BARC <br> Multi layer process materials NHC <br> Micro lens | LCD alignment coating bottom anti-reflective coating for semiconductors multi layer process material for semiconductors(Si-HM/SOC) protective coating for touch panel microlens material for image sensor application |
|  | Inorganic Materials SNOWTEX <br> Organo sillica sol Alumina sol SUNCOLLOID CELNAX | water dispersed colloidal sillica sol for polishing sillicon wafers, electrical steel sheets, NOx reduction catalyst, electronic printing materials film coating, antistatic interference shielding, electronic printing materials automotive catalyst, electronic printing materials high refractive sol for lens antistatic sol for film |
| Agro | ```Herbicide TARGA PERMIT SIRIUS, ALTAIR(NC-620) ROUNDUP Insecticide STARMITE, SANMITE, MITOKOHNE Fungicide LEIMAY PULSOR, IKARUGA, GREATAM (THIFLUZAMIDE)``` | soybean, rapeseed, sugarbeet <br> corn, sugarcane, rice <br> paddy rice <br> non-selective herbicide for orchard, noncrop land <br> fruits,tea, vegetables <br> potato, grape, turf |
| Pharma | LIVALO | Anti-cholesterol drug |
| Trading | Nissei Corporation |  |
| Others | Transportation, Landscaping, Engineering, Fertilizer |  |

## Main Products by Segment (Former Segmentation)

| Segment | Products | Main Applications |
| :---: | :---: | :---: |
| Chem | Organic Materials TEPIC Custom Chemicals Melamine cyanurate | epoxy compound for LED sealants, solder resist, painting custom manufacturing and process services for pharmaceutical companies flame retardant |
|  | Inorganic Materials SNOWTEX <br> Organo sillica sol Alumina sol SUNCOLLOID CELNAX | water dispersed colloidal sillica sol for polishing sillicon wafers, electrical steel sheets, NOx reduction catalyst, electronic printing materials <br> film coating, antistatic interference shielding, electronic printing materials automotive catalyst, electronic printing materials high refractive sol for lens antistatic sol for film |
|  | Basic Chemicals <br> Melamine <br> AdBlue <br> Environmetal product <br> Ammonia, Sulfuric acid, Nitric acid Highpurity chemicals | adhesive agent for plywood solution of urea in demineralised water for diesel trucks to reduce NOX HI-LITE (chlorinated isocyanuric acid for sterilizing) <br> agents used for cleaning semiconductors |
| Electronic Materials | SUNEVER <br> BARC <br> NHC <br> Micro lens | LCD alignment coating bottom anti-reflective coating for semiconductors protective coating for touch panel microlens material for image sensor application |
| Agro | ```Herbicide TARGA PERMIT SIRIUS, ALTAIR(NC-620) ROUNDUP Insecticide STARMITE, SANMITE, MITOKOHNE Fungicide LEIMAY PULSOR, IKARUGA, GREATAM (THIFLUZAMIDE)``` | soybean, rapeseed, sugarbeet corn, sugarcane, rice paddy rice non-selective herbicide for orchard, noncrop land <br> fruits,tea, vegetables <br> potato, grape, turf |
| Pharma | LIVALO | Anti-cholesterol drug |
| Trading | Nissei Corporation |  |
| Others | Transportation, Landscaping, Engineering, Fertilizer |  |

## Forward Looking Statements

The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.

No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.


Synonymous with excellence


[^0]:    (1) Asset impairment loss -0.3 by Nissan Chemical America Corporation (NCA) (Mainly production and marketing of Inorganic Materials)
    (2) EBITDA $=$ Operating Profit + Depreciation

